| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| IL-17F | Cynomolgus IL-17F Protein, His Tag | Cynomolgus | HEK293 | ![]() | SDS-PAGE | $395.00 100ug | ||
| IL-17F | HOTAvitag ILF-H82Q9 | Biotinylated Human IL-17F Protein, His,Avitag™ (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $415.00 25ug | |
| IL-17F | Human IL-17F Protein, His Tag, low endotoxin (Mass Spec & MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $200.00 20ug | ||
| IL-17F | Avitag ILF-C82Q3 | Biotinylated Cynomolgus IL-17F Protein, His,Avitag™ (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | |
| IL-17F | Human IL-17F (H161R) Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $165.00 20ug | ||
| IL-17F | Mouse IL-17F Protein, His Tag | Mouse | HEK293 | ![]() | SDS-PAGE | $395.00 100ug | ||
| IL-17F | Avitag ILF-M82Q3 | Biotinylated Mouse IL-17F Protein, His,Avitag™ (MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Sonelokimab | ALX-0761; MSB-0010841; M-1095 | Phase 3 Clinical | Ablynx Nv | Arthritis, Psoriatic; Hidradenitis Suppurativa; Psoriasis | Details |
| DMT-310 | DMT-310 | Phase 3 Clinical | Dermata | Acne Vulgaris; Rosacea | Details |
| ORKA-002 | ORKA-002; PR-029; ORKA-021 | Phase 2 Clinical | Paragon Therapeutics Inc | Arthritis, Psoriatic; Plaque psoriasis; Psoriasis | Details |
| PN-881 | PN-881 | Phase 1 Clinical | Protagonist Therapeutics Inc | Dermatitis; Psoriasis | Details |
| HY-1770 | HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |